Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.66 |
| ▸ | HTR2B | P41595 | 7/20 | 0.66 |
| ▸ | HSP90B1 | P14625 | 6/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.61 |
| ▸ | TMIGD3 | P0DMS9 | 4/20 | 0.61 |
| ▸ | TSPO | P30536 | 2/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21710880 | 0.89 | ADORA3 (0.65) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL25566756 | 0.89 | ADORA3 (0.65) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL19799159 | 0.84 | HSP90B1 (0.80) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL19459913 | 0.84 | HSP90B1 (0.80) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL19464999 | 0.80 | P2RY1 (0.57) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL19459458 | 0.77 | ADORA3 (0.77) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL19459476 | 0.77 | ADORA3 (0.77) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL19799165 | 0.77 | ADORA3 (0.77) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL19459456 | 0.77 | ADORA3 (0.77) | HTR2CHTR2BHSP90B1HSP90AA1ADORA1 | |
| SCHEMBL12269798 | 0.77 | P2RY1 (0.58) | HSP90B1HSP90AA1ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-9789131-B1 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | HTR2C 14/4885HTR2B 42/4885HSP90B1 3592/4885 |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | HTR2C 1443/4885HTR2B 1044/4885HSP90B1 1135/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | HTR2C 1443/4885HTR2B 1044/4885HSP90B1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.